Phased implementation of pathogen‐reduced platelets in a health system facilitates increased manufacturing at the blood center

BACKGROUND: Pathogen reduction treatment (PRT) reduces the risk of transfusion‐transmitted infections from established and emerging organisms. Manufacturing, however, is complex. In our university health system, we phased in pathogen‐reduced platelets (PR PLTs) by patient population. We then assesse...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen, Elizabeth S., Vincent, Colleen, Reeve, David A., Kopko, Patricia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Transfusion Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852374/
https://www.ncbi.nlm.nih.gov/pubmed/31408203
http://dx.doi.org/10.1111/trf.15480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852374/
https://www.ncbi.nlm.nih.gov/pubmed/31408203
http://dx.doi.org/10.1111/trf.15480

Ejemplares similares